{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:38:22Z","timestamp":1793367502105,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2021-RC310-005"],"award-info":[{"award-number":["2021-RC310-005"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32460247"],"award-info":[{"award-number":["32460247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019539","name":"Science Fund for Distinguished Young Scholars of Tianjin Municipality","doi-asserted-by":"publisher","award":["22JCJQJC00120"],"award-info":[{"award-number":["22JCJQJC00120"]}],"id":[{"id":"10.13039\/501100019539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2024-I2M-TS-028"],"award-info":[{"award-number":["2024-I2M-TS-028"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-2-008"],"award-info":[{"award-number":["2023-I2M-2-008"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2025-I2M-XHJC-048"],"award-info":[{"award-number":["2025-I2M-XHJC-048"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0139800"],"award-info":[{"award-number":["2022YFE0139800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["25ZXZSSS00290"],"award-info":[{"award-number":["25ZXZSSS00290"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116801","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:05:26Z","timestamp":1778137526000},"page":"116801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mechanistic insights and therapeutic innovation in immune-related adverse events"],"prefix":"10.1016","volume":"182","author":[{"given":"Zihao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2026.116801_bb0005","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2026.116801_bb0010","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.7150\/thno.58413","article-title":"Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes","volume":"11","author":"Xuan","year":"2021","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.intimp.2026.116801_bb0015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J. Immunother. Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009540","article-title":"Acknowledging and addressing real-world challenges to treating immune-related adverse events","volume":"12","author":"von Itzstein","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0035","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116801_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in Cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0070","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.intimp.2026.116801_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.intimp.2026.116801_bb0085","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0090","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates Cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0390-2","article-title":"Delayed onset of neurosarcoidosis after concurrent Ipilimumab\/Nivolumab therapy","volume":"6","author":"Tan","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of Colon inflammation induced by Cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2026.116801_bb0105","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying Immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41385-018-0113-5","article-title":"Tipping the balance: inhibitory checkpoints in intestinal homeostasis","volume":"12","author":"Joosse","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.intimp.2026.116801_bb0125","first-page":"33","article-title":"Bridging the gap: connecting the mechanisms of immune-related adverse events and autoimmunity through PD-1","volume":"9","author":"Mor","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0130","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0135","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1172\/JCI129018","article-title":"E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases","volume":"130","author":"Wang","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2026.116801_bb0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116801_bb0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ebiom.2024.105427","article-title":"Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors","volume":"109","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7971","key":"10.1016\/j.intimp.2026.116801_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6184","key":"10.1016\/j.intimp.2026.116801_bb0165","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial Cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.intimp.2026.116801_bb0170","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116801_bb0175","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2026.116801_bb0180","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with Axicabtagene Ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0185","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of Neurofilament Light Chain levels in patients who develop Immune Effector Cell\u2013Associated Neurotoxicity Syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0195","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","article-title":"Engineering immune-evasive allogeneic cellular immunotherapies","volume":"24","author":"Martin","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116801_bb0200","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0205","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nature Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0210","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0220","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0225","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0230","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.molmed.2012.07.007","article-title":"Recombinant viral vaccines for cancer","volume":"18","author":"Cawood","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0235","first-page":"450","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"10.1016\/j.intimp.2026.116801_bb0245","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO-10: a phase I study of intravenous Reovirus and docetaxel in patients with advanced Cancer","volume":"16","author":"Comins","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0250","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0260","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1021\/acsnano.9b05115","article-title":"Nanodelivery of mycophenolate Mofetil to the organ improves transplant vasculopathy","volume":"13","author":"Uehara","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.116801_bb0265","doi-asserted-by":"crossref","unstructured":"H. Yang, J. Wang, X. Zhang, Y. Zhang, Z.-l. Qin, H. Wang, X.-y. Luo, Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and Meta-analysis, JAMA Dermatol. 155(5) (2019) 585\u2013593. doi:https:\/\/doi.org\/10.1001\/jamadermatol.2019.0008.","DOI":"10.1001\/jamadermatol.2019.0008"},{"issue":"10","key":"10.1016\/j.intimp.2026.116801_bb0270","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.20140039","article-title":"Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders","volume":"211","author":"Perreau","year":"2014","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-021-00626-z","article-title":"Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin Levels, infectious risk, and mortality with rituximab and Hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"16","key":"10.1016\/j.intimp.2026.116801_bb0285","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2022.40.16_suppl.2665","article-title":"Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series","volume":"40","author":"Harvey","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116801_bb0290","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1200\/JCO.2023.41.16_suppl.e15017","article-title":"Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib","volume":"41","author":"Skorupan","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0295","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2352-3026(15)00283-5","article-title":"Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests: a single-institution propensity-adjusted cohort study","volume":"3","author":"Jia","year":"2016","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.intimp.2026.116801_bb0305","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0315","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0320","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0325","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0330","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0335","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0340","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41422-019-0184-1","article-title":"Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy","volume":"29","author":"Zhang","year":"2019","journal-title":"Cell Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.116801_bb0345","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0350","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0355","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"10183","key":"10.1016\/j.intimp.2026.116801_bb0360","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0365","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116801_bb0370","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0375","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013Programmed Death-1\/Programmed Death Ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116801_bb0380","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2020.10.476","article-title":"Pulmonary toxicity in patients treated with immune checkpoint inhibitors and radiation","volume":"31","author":"Senan","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0385","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events with Nivolumab Efficacy in non\u2013small-cell lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116801_bb0390","first-page":"695","article-title":"Detection of subclinical cardiovascular disease by cardiovascular magnetic resonance in lymphoma survivors","volume":"3","author":"van der Velde","year":"2021","journal-title":"JACC: CardioOncology"},{"issue":"17","key":"10.1016\/j.intimp.2026.116801_bb0395","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of Immune Checkpoint Inhibitor\u2013based combination therapy in patients with advanced Renal Cell Cancer: data from the Phase III JAVELIN Renal 101 Trial","volume":"40","author":"Rini","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116801_bb0400","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.intimp.2026.116801_bb0405","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0415","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0420","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.ajkd.2015.10.023","article-title":"Kidney disease in adenine Phosphoribosyltransferase deficiency","volume":"67","author":"Runolfsdottir","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0425","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0430","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116801_bb0435","doi-asserted-by":"crossref","first-page":"227722","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of Immune Checkpoint Inhibitors with Neurologic Adverse Events: a systematic review and Meta-analysis","volume":"5","author":"Farooq","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0440","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","article-title":"Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma","volume":"116","author":"Hutter","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0445","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116801_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1743245","article-title":"Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review","volume":"16","author":"Dong","year":"2026","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0455","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0460","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract. Res. Clin. Endoc. Metab."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0465","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/cancers16071340","article-title":"Early serum markers for immune checkpoint inhibitor induced Hypophysitis in melanoma patients","volume":"16","author":"Mitri","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116801_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101787","article-title":"Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency","volume":"38","author":"Xiang","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.116801_bb0475","article-title":"Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency","volume":"15","author":"Huang","year":"2025","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116801_bb0480","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eprac.2020.12.009","article-title":"Real-world evidence of the incidence of and risk factors for type 1 diabetes mellitus and hypothyroidism as immune-related adverse events associated with programmed cell Death-1 inhibitors","volume":"27","author":"Shimada","year":"2021","journal-title":"Endocr. Pract."},{"issue":"10","key":"10.1016\/j.intimp.2026.116801_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0490","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and De novo inflammatory arthritis after immune checkpoint inhibitor treatment for Cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0495","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BOR.0000000000000935","article-title":"Rheumatologic immune checkpoint inhibitor-related adverse events","volume":"35","author":"Defoe","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116801_bb0500","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.intimp.2026.116801_bb0505","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert perspective: immune checkpoint inhibitors and rheumatologic complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis & Rheumatology"},{"issue":"16","key":"10.1016\/j.intimp.2026.116801_bb0510","article-title":"Rare immune-related adverse events: a retrospective analysis from a single-center cohort study","volume":"43","author":"Trivedi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116801_bb0515","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0520","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"23","key":"10.1016\/j.intimp.2026.116801_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201703","article-title":"Polypyrrole Nanoenzymes as tumor microenvironment modulators to reprogram macrophage and potentiate immunotherapy","volume":"9","author":"Zeng","year":"2022","journal-title":"Adv. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.116801_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007557","article-title":"Nanoparticle-mediated delivery of inhaled Immunotherapeutics for treating lung metastasis","volume":"33","author":"Jin","year":"2021","journal-title":"Adv. Mater."},{"issue":"20","key":"10.1016\/j.intimp.2026.116801_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206213","article-title":"Microfluidics-enabled Nanovesicle delivers CD47\/PD-L1 antibodies to enhance antitumor immunity and reduce Immunotoxicity in lung adenocarcinoma","volume":"10","author":"Su","year":"2023","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0540","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cell.2015.03.037","article-title":"Immunoengineering: how nanotechnology can enhance cancer immunotherapy","volume":"161","author":"Goldberg","year":"2015","journal-title":"Cell"},{"issue":"49","key":"10.1016\/j.intimp.2026.116801_bb0545","doi-asserted-by":"crossref","first-page":"33366","DOI":"10.1021\/acsnano.4c08448","article-title":"Anti-PD-L1 antibody fragment linked to tumor-targeting lipid nanoparticle can eliminate Cancer and its metastasis via Photoimmunotherapy","volume":"18","author":"Park","year":"2024","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0550","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/acs.accounts.0c00339","article-title":"Local and targeted delivery of immune checkpoint blockade therapeutics","volume":"53","author":"Han","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.intimp.2026.116801_bb0555","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-319-95294-9_12","article-title":"Platelet-based drug delivery for Cancer applications","volume":"1092","author":"Ortiz-Otero","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116801_bb0560","doi-asserted-by":"crossref","first-page":"0011","DOI":"10.1038\/s41551-016-0011","article-title":"In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy","volume":"1","author":"Wang","year":"2017","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.intimp.2026.116801_bb0565","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","article-title":"Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel","volume":"7","author":"Li","year":"2023","journal-title":"Nat. Biomed. Eng"},{"issue":"7756","key":"10.1016\/j.intimp.2026.116801_bb0570","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0575","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41590-022-01262-7","article-title":"Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy","volume":"23","author":"Boukhaled","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116801_bb0580","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1\u2013based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0585","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-025-02246-5","article-title":"Hijacking of the nervous system in cancer: mechanism and therapeutic targets","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8017","key":"10.1016\/j.intimp.2026.116801_bb0590","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41586-024-07469-y","article-title":"A body\u2013brain circuit that regulates body inflammatory responses","volume":"630","author":"Jin","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2026.116801_bb0595","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.it.2014.07.010","article-title":"Modulation of immune development and function by intestinal microbiota","volume":"35","author":"Kabat","year":"2014","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0600","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116801_bb0605","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-021-00923-w","article-title":"Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer","volume":"13","author":"Hayase","year":"2021","journal-title":"Genome Med."},{"issue":"44","key":"10.1016\/j.intimp.2026.116801_bb0610","doi-asserted-by":"crossref","first-page":"27509","DOI":"10.1073\/pnas.1921223117","article-title":"Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade","volume":"117","author":"Sun","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6678","key":"10.1016\/j.intimp.2026.116801_bb0615","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.adh8342","article-title":"Microbiota-dependent activation of CD4+ T cells induces CTLA-4 blockade associated colitis via fc receptors","volume":"383","author":"Lo","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2026.116801_bb0620","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ccell.2024.03.001","article-title":"Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy","volume":"42","author":"Xue","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116801_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.153939","article-title":"Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR\/JAK1\/STAT3 pathway to inhibit PD-1\/PD-L1 checkpoint signaling","volume":"99","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.intimp.2026.116801_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.12.016","article-title":"Secondary metabolites of mulberry leaves exert anti-lung cancer activity through regulating the PD-L1\/PD-1 signaling pathway","volume":"14","author":"Ye","year":"2024","journal-title":"J. Pharm. Anal."},{"issue":"10","key":"10.1016\/j.intimp.2026.116801_bb0635","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.phymed.2016.06.010","article-title":"Gegen Qinlian decoction alleviates experimental colitis via suppressing TLR4\/NF-\u03baB signaling and enhancing antioxidant effect","volume":"23","author":"Li","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116801_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104603","article-title":"Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-\u03baB pathway","volume":"152","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116801_bb0645","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic\u2013immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116801_bb0650","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fphar.2025.1661503","article-title":"Efficacy and safety of traditional Chinese medicine (TCM) combined with immune checkpoint inhibitors (ICIs) for the treatment of cancer: a systematic review and meta-analysis","volume":"16","author":"Ke","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116801_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112301","article-title":"Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: a real-world pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database (2014\u20132022)","volume":"136","author":"Ren","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116801_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2026.116801_bb0665","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:59:03Z","timestamp":1789243143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":133,"alternative-id":["S1567576926006478"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116801","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights and therapeutic innovation in immune-related adverse events","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116801"}}